Skip to main content
Sign In

CU Denver CU Anschutz Resources Schools & Colleges

 

Kenneth A. Lichtenstein, MD

Professor of Medicine
 

 

Phone 303-398-1930
E-mail lichtensteink@njc.org
Address National Jewish Medical and Research Center
1400 Jackson Street, G316
Denver, CO 80206

 

Medical School
University of Colorado

Residency
Internal Medicine - University of Colorado School of Medicine 

Fellowship
Infectious Diseases - University of Colorado School of Medicine 

 

 

Dr. Lichtenstein conducts epidemiologic research in conjunction with the Centers for Disease Control and Prevention (CDC) on outcomes in HIV infection. Main area of interest is the role of the virus and the state of chronic inflammation induced by the virus on HIV-associated co-morbidities such as lipodystrophy, cardiovascular disease, endocrinologic disorders, and nucleoside-associated toxicities.

1) Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389098.

2) Kosmiski L, Kuritzkes D, Lichtenstein KA, et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001; 15:1-8.

3) Kosmiski L, Kuritzkes D, Lichtenstein KA, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 2003; 8(1):9-15.

4) Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. JAIDS. 2003; 32:48-56.

5) Anderson PL, Kakuda TN, Lichtenstein KL. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis. 2004;38:743-53.

6) Holmberg SD, Palella FJ, Lichtenstein KA, Havlir DV. The case for earlier treatment of HIV infection. Clin Infect Dis. 2004; 39:1699-704.

7) Lichtenstein KA, Armon C, Moorman AC, et al. A 7-year longitudinal analysis of IL-2 in patients treated with highly active antiretroviral therapy. AIDS. 2004;18,17:4-6.

8) Lichtenstein KA, Armon C, Baron A, et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV Outpatient cohort. Clin Infec Dis. 2005; 40:148-157.

9) Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. JAIDS. 2005; 39(4): 395-400.